Skip to main content
Caplight Logo









Typewriter Therapeutics

Typewriter Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.typewritertx.com/en/

Last Round

Series A

Sep 2, 2026

Total Funding Raised

$61M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Typewriter Therapeutics is a biotechnology company that is developing a ribonucleic acid (RNA) based gene writing therapeutic platform for the targeted insertion of therapeutic genes to treat severe genetic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

gene writingmRNA gene therapygene therapy platformtargeted gene insertionRNA therapeuticstransposon technologysevere genetic disordersgenetic medicinesgene therapyRNA deliverybiotechnologydrug discoveryprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Typewriter Therapeutics Comparables

Compare Typewriter Therapeutics with similar companies based on industry and business-model similarity.

Typewriter Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Averna Therapeutics
84%
Tessera Therapeutics
84%
Integra Therapeutics
81%

Typewriter Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 2, 2026
GrantDec 22, 2024
SeedFeb 27, 2024

Typewriter Therapeutics Investors

Notable investors and investment history

Typewriter Therapeutics investors
InvestorRounds
Japan Agency for Medical Research and DevelopmentGrant
RA Capital ManagementSeed, Series A
ANRI株式会社Seed, Series A
AN Venture PartnersSeed, Series A
SBI HoldingsSeries A
Gemseki Investment Inc.Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 2, 2026

    $56M round led by AN Venture Partners and RA Capital Management.

  • May 18, 2026

    Monthly visitors increased 69% MoM.

Typewriter Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Typewriter Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Typewriter Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range33
Year Founded2022
Last FundingSep 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?